Market Cap 4.11B
Revenue (ttm) 336.89M
Net Income (ttm) -87.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -26.10%
Debt to Equity Ratio 0.00
Volume 241,900
Avg Vol 667,136
Day's Range N/A - N/A
Shares Out 51.39M
Stochastic %K 91%
Beta 0.42
Analysts Strong Sell
Price Target $103.10

Company Profile

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercializat...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 667 4085
Address:
950 Tower Lane, Suite 1050, Foster City, United States
LMXPERTEN
LMXPERTEN Dec. 22 at 5:58 PM
$MIRM good to see you woke up
0 · Reply
JFais
JFais Dec. 22 at 1:55 PM
$MIRM $NUVB - both great examples of how BD-savvy mgmt adds LT optionality (highly attractive in terms of stock selection criteria)
0 · Reply
godric060583
godric060583 Dec. 19 at 6:29 PM
$MIRM float dynamics matter more than headlines 🚀
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 5:24 PM
Actionable Trade Alert for $MIRM: Market Context: $MIRM is currently trading at $70.28, showing a neutral sentiment with an RSI of 43.25, indicating potential for upward movement as it is below the 50 threshold. The price is above the 30-day moving average (MA30) of 69.45 but slightly below the 50-day moving average (MA50) of 70.4, suggesting a consolidation phase. Directional Bias: Given the RSI and proximity to MA30 and MA50, there is a slight bullish bias. The 60-day high of 78.54 presents a target opportunity, while the low of 63.23 indicates a support level. Suggested Trade Plan: - Entry: $70.50 (slightly above the last close to confirm momentum) - Stop Loss: $67.50 (below recent support) - Take Profit Targets: 1. $74.00 (5% gain) 2. $76.00 (8% gain) 3. $82.00 (17% gain) This plan leverages the potential upside towards the 60-day high while managing risk effectively. https://privateprofiteers.com
0 · Reply
LMXPERTEN
LMXPERTEN Dec. 19 at 4:43 PM
$MIRM do you remember that amateur who sold all at 25ish? Behaved like a sh*thole. Anyone recall the 🤡 ’s nick? Jeeessus
0 · Reply
WAJeff
WAJeff Dec. 19 at 4:30 PM
$MIRM 19 cents from another ath. Just sold at $78 but keeping on dip watch
1 · Reply
xbibackto1milly
xbibackto1milly Dec. 19 at 3:56 PM
$MIRM beast
0 · Reply
LMXPERTEN
LMXPERTEN Dec. 19 at 3:54 PM
$MIRM finally some intelligent analyst, citizens. Boat fully loaded every irrational drop 😇
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 19 at 3:39 PM
0 · Reply
stockpicker63
stockpicker63 Dec. 19 at 3:35 PM
Watch today $MIRM target $85 and $AA target $54.
0 · Reply
Latest News on MIRM
Mirum Pharmaceuticals, Inc. (MIRM) M&A Call Transcript

Dec 8, 2025, 4:17 PM EST - 16 days ago

Mirum Pharmaceuticals, Inc. (MIRM) M&A Call Transcript


Volixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL

May 9, 2025, 8:30 AM EDT - 8 months ago

Volixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL


Mirum's LIVMARLI Now FDA Approved in Tablet Formulation

Apr 14, 2025, 8:30 AM EDT - 9 months ago

Mirum's LIVMARLI Now FDA Approved in Tablet Formulation


LIVMARLI Now Approved in Japan for ALGS and PFIC

Mar 27, 2025, 8:30 AM EDT - 9 months ago

LIVMARLI Now Approved in Japan for ALGS and PFIC


US FDA approves Mirum Pharma's genetic disorder drug

Feb 21, 2025, 12:01 PM EST - 10 months ago

US FDA approves Mirum Pharma's genetic disorder drug


Mirum Pharma: Buy At Dips For Volixibat Potential

Dec 25, 2024, 10:00 AM EST - 1 year ago

Mirum Pharma: Buy At Dips For Volixibat Potential


LMXPERTEN
LMXPERTEN Dec. 22 at 5:58 PM
$MIRM good to see you woke up
0 · Reply
JFais
JFais Dec. 22 at 1:55 PM
$MIRM $NUVB - both great examples of how BD-savvy mgmt adds LT optionality (highly attractive in terms of stock selection criteria)
0 · Reply
godric060583
godric060583 Dec. 19 at 6:29 PM
$MIRM float dynamics matter more than headlines 🚀
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 19 at 5:24 PM
Actionable Trade Alert for $MIRM: Market Context: $MIRM is currently trading at $70.28, showing a neutral sentiment with an RSI of 43.25, indicating potential for upward movement as it is below the 50 threshold. The price is above the 30-day moving average (MA30) of 69.45 but slightly below the 50-day moving average (MA50) of 70.4, suggesting a consolidation phase. Directional Bias: Given the RSI and proximity to MA30 and MA50, there is a slight bullish bias. The 60-day high of 78.54 presents a target opportunity, while the low of 63.23 indicates a support level. Suggested Trade Plan: - Entry: $70.50 (slightly above the last close to confirm momentum) - Stop Loss: $67.50 (below recent support) - Take Profit Targets: 1. $74.00 (5% gain) 2. $76.00 (8% gain) 3. $82.00 (17% gain) This plan leverages the potential upside towards the 60-day high while managing risk effectively. https://privateprofiteers.com
0 · Reply
LMXPERTEN
LMXPERTEN Dec. 19 at 4:43 PM
$MIRM do you remember that amateur who sold all at 25ish? Behaved like a sh*thole. Anyone recall the 🤡 ’s nick? Jeeessus
0 · Reply
WAJeff
WAJeff Dec. 19 at 4:30 PM
$MIRM 19 cents from another ath. Just sold at $78 but keeping on dip watch
1 · Reply
xbibackto1milly
xbibackto1milly Dec. 19 at 3:56 PM
$MIRM beast
0 · Reply
LMXPERTEN
LMXPERTEN Dec. 19 at 3:54 PM
$MIRM finally some intelligent analyst, citizens. Boat fully loaded every irrational drop 😇
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 19 at 3:39 PM
0 · Reply
stockpicker63
stockpicker63 Dec. 19 at 3:35 PM
Watch today $MIRM target $85 and $AA target $54.
0 · Reply
Baerchen
Baerchen Dec. 19 at 3:20 PM
$MIRM Best investment ever yet, luckily I got in when they where around 14$ and only available on NASDAQ - smart people strengthening their liver-portfolio and leaving out obesity/MASH/cardio/metabolic. Since Merck was fine in paying 9B$ on Cidara - let's see if Gilead or some european competitors like GSK/Sanofi will find interest in them. Since Trump wants to cut healthcare costs - in Europe they will still be able to make income. And if the Hep D-Vac works, get access to eastern Europe and Asia - it will be a big market. Since Gilead alread has a Hep D-Vac - it is time for some overtake from Europe.
0 · Reply
JarvisFlow
JarvisFlow Dec. 19 at 1:31 PM
Citizens has updated their rating for Mirum Pharmaceuticals ( $MIRM ) to Market Outperform with a price target of 140.
0 · Reply
Quantumup
Quantumup Dec. 19 at 12:42 PM
Citizens⬆️ $MIRM's PT to $140 from $95, reit'd at Market Outperform, and said, MIRM shares are up 70% YTD (vs. $XBI's 33% gain) and we expect continued outperformance in 2026 driven by pivotal readouts across the pipeline where we have high confidence. $GILD $GSK $VIR Citizens went on to say: https://x.com/Quantumup1/status/2001995805201207779?s=20
0 · Reply
ZacksResearch
ZacksResearch Dec. 18 at 7:21 PM
Is $MIRM setting up for another big revenue year in 2026? 🚀 Livmarli sales surged 70% in the first nine months of 2025, and expanding approvals plus broader commercialization are expected to keep the revenue momentum rolling into 2026. Find out what’s driving the growth story here 👉 https://www.zacks.com/stock/news/2806269/will-strong-livmarli-uptake-continue-to-aid-mirms-revenues-in-2026?cid=sm-stocktwits-2-2806269-teaser-25529&ADID=SYND_STOCKTWITS_TWEET_2_2806269_TEASER_25529
0 · Reply
ZacksResearch
ZacksResearch Dec. 18 at 6:21 PM
$MIRM's stock surges 35.9% in 6 months — what's driving the rally? 🚀 Livmarli sales jump 70% in the first nine months of 2025, with expectations for continued growth and new product formulations boosting convenience. Plus, updated revenue guidance reflects strong product adoption and diversification. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2806269/will-strong-livmarli-uptake-continue-to-aid-mirms-revenues-in-2026?cid=sm-stocktwits-2-2806269-body-25528&ADID=SYND_STOCKTWITS_TWEET_2_2806269_BODY_25528
0 · Reply
BostonNorth
BostonNorth Dec. 18 at 2:54 PM
$SPRY $NDAQ $GME $KBIO $MIRM $SIGA Borrow cost is no longer cheap or stable…. Rent is going up…landlord knows supply is tight.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 17 at 4:09 AM
Actionable Trade Alert for $MIRM Market Context: $MIRM closed at $67.05, below its 30-day (MA30) and 50-day (MA50) moving averages, indicating a bearish trend. However, the RSI at 37.44 suggests the stock is oversold, presenting a potential reversal opportunity. Directional Bias: Given the current RSI and proximity to the 60-day low of $63.23, there is a bullish bias for a short-term recovery towards the 60-day high of $78.54. The ATR of $3.14 indicates moderate volatility, allowing for potential price movement. Trade Plan: - Suggested Entry: $67.05 - Stop Loss: $63.00 (below the 60D low) - Take Profit Targets: 1. $71.00 (10.4% ROI) 2. $75.00 (11.8% ROI) 3. $78.00 (16.3% ROI) The third target provides a potential return of over 17% from the entry point. Monitor the trade closely for any changes in market conditions. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
IN0V8
IN0V8 Dec. 16 at 8:47 PM
$MIRM Buy Stifel raises target price to $98 from $92
0 · Reply
erevnon
erevnon Dec. 16 at 6:57 PM
Stifel maintains Mirum Pharmaceuticals $MIRM at Buy and raises the price target from $92 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Bornjever
Bornjever Dec. 16 at 5:31 PM
$MIRM we just purchased a company called Bluejay Therapeutics that is also in the liver diseases area and we are now much stronger in the same business with talented folks joining us and working for stronger and better delivery and efficacy of our products. I have been on wonderful journey with MIRM and this will only make it batter.
1 · Reply
JarvisFlow
JarvisFlow Dec. 16 at 5:28 PM
Stifel has updated their rating for Mirum Pharmaceuticals ( $MIRM ) to Buy with a price target of 98.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 7:42 AM
Actionable Trade Alert for $MIRM: Market Context: $MIRM is currently trading at $65.00, below its 30-day (MA30) and 50-day (MA50) moving averages, indicating a bearish trend. However, the RSI at 31.99 suggests the stock is oversold, potentially setting up for a reversal. Directional Bias: The stock is near its 60-day low of $63.48, providing a support level. The oversold RSI indicates a possible bounce back, while the distance to the 60-day high of $78.54 allows for significant upside potential. Trade Plan: - Suggested Entry: $65.00 - Stop Loss: $62.00 (to limit risk) - Take Profit Targets: 1. Target 1: $70.00 (7.69% ROI) 2. Target 2: $73.00 (12.31% ROI) 3. Target 3: $76.00 (16.92% ROI) This plan provides a clear path for profit while managing risk effectively. Monitor the stock closely for any changes in momentum. https://privateprofiteers.com
0 · Reply